Total Payments
$3.1M
2024 Payments
$268,909
Companies
56
Transactions
2,275
Medicare Patients
347
Medicare Billing
$74,496
Payment Breakdown by Category
Other$1.9M (62.0%)
Consulting$783,163 (25.4%)
Travel$277,370 (9.0%)
Research$75,643 (2.4%)
Food & Beverage$36,708 (1.2%)
Education$5.56 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.8M | 658 | 58.3% |
| Consulting Fee | $783,163 | 245 | 25.4% |
| Travel and Lodging | $277,370 | 692 | 9.0% |
| Honoraria | $109,352 | 50 | 3.5% |
| Unspecified | $75,643 | 34 | 2.4% |
| Food and Beverage | $36,708 | 592 | 1.2% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $3,000 | 1 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,250 | 1 | 0.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,250 | 1 | 0.0% |
| Education | $5.56 | 1 | 0.0% |
Payments by Type
General
$3.0M
2,241 transactions
Research
$75,643
34 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $762,199 | 537 | $0 (2024) |
| Genentech USA, Inc. | $385,012 | 261 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $261,150 | 193 | $0 (2024) |
| Lilly USA, LLC | $212,918 | 172 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $211,450 | 208 | $0 (2024) |
| Janssen Biotech, Inc. | $149,523 | 116 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $130,051 | 121 | $0 (2024) |
| F. Hoffmann-La Roche AG | $121,184 | 73 | $0 (2024) |
| G1 Therapeutics, Inc. | $101,646 | 54 | $0 (2023) |
| Celgene Corporation | $101,563 | 86 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $268,909 | 229 | Janssen Biotech, Inc. ($76,989) |
| 2023 | $351,920 | 260 | AstraZeneca Pharmaceuticals LP ($99,244) |
| 2022 | $434,955 | 267 | JAZZ PHARMACEUTICALS INC. ($83,518) |
| 2021 | $430,805 | 302 | Lilly USA, LLC ($93,217) |
| 2020 | $288,112 | 169 | AstraZeneca Pharmaceuticals LP ($101,356) |
| 2019 | $424,070 | 284 | AstraZeneca Pharmaceuticals LP ($122,061) |
| 2018 | $401,468 | 323 | AstraZeneca Pharmaceuticals LP ($107,309) |
| 2017 | $488,085 | 441 | E.R. Squibb & Sons, L.L.C. ($141,199) |
All Payment Transactions
2,275 individual payment records from CMS Open Payments — Page 1 of 91
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $549.07 | Research |
| Study: Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $534.41 | Research |
| Study: Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 | ||||||
| 12/31/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | Cash or cash equivalent | $160.56 | General |
| Category: Oncology | ||||||
| 12/30/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | In-kind items and services | $1,165.50 | General |
| Category: Oncology | ||||||
| 12/23/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,070.00 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $89.80 | General |
| Category: Oncology | ||||||
| 12/11/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | Travel and Lodging | Cash or cash equivalent | $8,737.07 | General |
| Category: BioOncology | ||||||
| 12/11/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $780.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/11/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | Travel and Lodging | Cash or cash equivalent | $658.86 | General |
| Category: BioOncology | ||||||
| 12/11/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $481.65 | General |
| Category: BioOncology | ||||||
| 12/11/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $258.11 | General |
| Category: BioOncology | ||||||
| 12/11/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | Travel and Lodging | Cash or cash equivalent | $79.60 | General |
| Category: BioOncology | ||||||
| 12/09/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,070.00 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $94.84 | General |
| Category: HEMATOLOGY | ||||||
| 12/06/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $1,575.00 | General |
| Category: Oncology | ||||||
| 12/04/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,020.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/04/2024 | F. Hoffmann-La Roche AG | — | Consulting Fee | Cash or cash equivalent | $2,280.00 | General |
| 12/04/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | In-kind items and services | $871.13 | General |
| Category: Oncology | ||||||
| 12/04/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Travel and Lodging | In-kind items and services | $169.78 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | Cash or cash equivalent | $98.68 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | Cash or cash equivalent | $16.32 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | Cash or cash equivalent | $2.97 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $13.41 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Travel and Lodging | In-kind items and services | $11.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $9,700 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $8,750 | 1 |
| A phase III, open-label, randomized study of MPDL3280A anti-PDL-1 antibody in combination with carboplatin paclitaxel with or without Bevacizumab compared with carboplatin paclitaxel bevacizumab in chemotherapy-naive patients with stage IV non-squamous non-small cell lung cancer | F. Hoffmann-La Roche AG | $5,596 | 7 |
| A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction with nab-Paclitaxel Plus Carboplatin in subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC) (ABI-007-NSCL-003) | Celgene Corporation | $5,163 | 1 |
| A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB MPDL3280A, ANTI-PD-L1 ANTIBODY IN COMBINATION WITH CARBOPLATIN PACLITAXEL OR ATEZOLIZUMAB IN COMBINATION WITH CARBOPLATINNAB PACLITAXEL VERSUS CARBOPLATINNAB-PACLITAXEL IN CHEMOTHERAPY NAIVE PATIENTS WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER | F. Hoffmann-La Roche AG | $4,659 | 1 |
| CRIZOTINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,600 | 2 |
| GEDATOLISIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| NIROGACESTAT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| PF06647263 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A ANTI-PDL-1 ANTIBODY IN COMBINATION WITH CARBOPLATIN PACLITAXEL WITH OR WITHOUT BEVACIZUMAB COMPARED WITH CARBOPLATIN PACLITAXEL BEVACIZUMAB IN CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER, A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB MPDL3280A, ANTI-PD-L1 ANTIBODY IN COMBINATION WITH CARBOPLATIN OR CISPLATIN PEMETREXED COMPARED WITH CARBOPLATIN OR CISPLATIN PEMETREXED IN PATIENT | F. Hoffmann-La Roche AG | $3,140 | 2 |
| A phase III, open-label, randomized study of MPDL3280A anti-PDL-1 antibody in combination with carboplatin paclitaxel with or without Bevacizumab compared with carboplatin paclitaxel bevacizumab in chemotherapy-naive patients with stage IV non-squamous non-small cell lung cancer, A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY COMPARED WITH DOCETAXEL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AFTER | F. Hoffmann-La Roche AG | $2,884 | 1 |
| A Phase II, Single Arm, Open-Label, Multicenter, Safety and Tolerability Trial with Nab-Paclitaxel (ABRAXANE ) Plus Carboplatin Followed by Nab-Paclitaxel Monotherapy as First-Line Treatment for Subjects with Locally Advanced or Metastatic Nonsmall Cell Lung Cancer (NSCLC) and an Eastern Cooperative Oncology Group Performance Status of 2 (ABOUND.PS2) (ABI-007-NSCL-004) | Celgene Corporation | $2,866 | 1 |
| CA031 - A Randomized, Phase III Trial ofABI-007 and Carboplatin Compared with Taxol and Carboplatin as First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) | Celgene Corporation | $2,866 | 1 |
| CA031 | Celgene Corporation | $2,533 | 1 |
| A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A ANTI-PDL-1 ANTIBODY IN COMBINATION WITH CARBOPLATIN PACLITAXEL WITH OR WITHOUT BEVACIZUMAB COMPARED WITH CARBOPLATIN PACLITAXEL BEVACIZUMAB IN CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER | F. Hoffmann-La Roche AG | $2,529 | 3 |
| ABI-007-NSCL-003 | Celgene Corporation | $1,734 | 1 |
| A PHASE II SINGLE-ARM STUDY OF ATEZOLIZUMAB MONOTHERAPY IN LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER CLINICAL EVALUATION OF NOVEL BLOOD-BASED DIAGNOSTICS | F. Hoffmann-La Roche AG | $1,537 | 1 |
| ABI-007-NSCL-006 - A Phase 2, Open-Label, Multi-Center Study to Assess Safety and Efficacy of Second/Third-Line Treatment With NAB®-Paclitaxel (ABI-007) In Combination With Epigenetic Modifying Therapy Of CC-486, Or Im | Celgene Corporation | $1,524 | 1 |
| Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 | F. Hoffmann-La Roche AG | $1,083 | 2 |
| A phase III, open-label, randomized study of MPDL3280A (anti-PDL-1 antibody) in combination with carboplatin + paclitaxel with or without Bevacizumab compared with carboplatin + paclitaxel + bevacizumab in chemotherapy-naive patients with stage IV non-squamous non-small cell lung cancer | F. Hoffmann-La Roche AG | $1,021 | 1 |
| A Phase III, Open-Label, Randomized Study of Atezolizumab MPDL3280A, Anti-Pd-L1 Antibody in Combination With Carboplatin or Cisplatin Pemetrexed Compared With Carboplatin or Cisplatin Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer | F. Hoffmann-La Roche AG | $425.79 | 1 |
| All Comers SSF | F. Hoffmann-La Roche AG | $230.94 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 78 | 162 | $70,355 | $17,843 |
| 2022 | 3 | 82 | 165 | $71,376 | $16,583 |
| 2021 | 3 | 81 | 215 | $80,608 | $20,722 |
| 2020 | 5 | 106 | 252 | $74,945 | $19,348 |
Total Patients
347
Total Services
794
Medicare Billing
$74,496
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 44 | 123 | $46,886 | $11,757 | 25.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 21 | 21 | $13,865 | $3,703 | 26.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 13 | 18 | $9,604 | $2,384 | 24.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 46 | 126 | $48,104 | $11,345 | 23.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 18 | 21 | $11,343 | $2,747 | 24.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 18 | 18 | $11,929 | $2,491 | 20.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 43 | 147 | $57,052 | $14,478 | 25.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 26 | 43 | $23,331 | $6,170 | 26.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 12 | 25 | $225.00 | $75.00 | 33.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 40 | 138 | $45,264 | $11,410 | 25.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 20 | 39 | $17,199 | $4,218 | 24.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 17 | 17 | $10,744 | $2,667 | 24.8% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 12 | 16 | $1,360 | $927.21 | 68.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 17 | 42 | $378.00 | $125.52 | 33.2% |
About Dr. Mark Socinski, MD
Dr. Mark Socinski, MD is a Hematology & Oncology healthcare provider based in Orlando, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1740341726.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Socinski, MD has received a total of $3.1M in payments from pharmaceutical and medical device companies, with $268,909 received in 2024. These payments were reported across 2,275 transactions from 56 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.8M).
As a Medicare-enrolled provider, Socinski has provided services to 347 Medicare beneficiaries, totaling 794 services with total Medicare billing of $74,496. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Orlando, FL
- Active Since 12/13/2006
- Last Updated 08/24/2016
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1740341726
Products in Payments
- TAGRISSO (Drug) $450,197
- TECENTRIQ (Biological) $291,860
- ZEPZELCA (Drug) $261,092
- OPDIVO (Biological) $193,268
- IMFINZI (Drug) $172,194
- LIBTAYO (Biological) $155,941
- RYBREVANT (Drug) $148,602
- IMFINZI (Biological) $123,537
- COSELA (Drug) $101,683
- Abraxane (Drug) $100,932
- ALUNBRIG (Drug) $64,290
- Vitrakvi (Drug) $56,758
- Alecensa (Biological) $52,954
- RETEVMO (Drug) $51,734
- GILOTRIF (Drug) $46,836
- KEYTRUDA (Biological) $43,095
- Tecentriq (Biological) $40,058
- Avastin (Biological) $39,969
- KRAZATI (Drug) $38,378
- CYRAMZA (Drug) $29,279
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Orlando
Tarek Mekhail, M.d, M.D
Hematology & Oncology — Payments: $2.7M
Hematology & Oncology $2.7M
Dr. Daniel Landau, Md, MD
Hematology & Oncology — Payments: $2.0M
Hematology & Oncology $2.0M
Sajeve Thomas, Md, MD
Hematology & Oncology — Payments: $843,415
Hematology & Oncology $843,415
Rebecca Moroose, Md, MD
Hematology & Oncology — Payments: $790,811
Hematology & Oncology $790,811
Dr. Nikita Shah, Md, MD
Hematology & Oncology — Payments: $493,804
Hematology & Oncology $493,804
Dr. Guru Sonpavde, Md, MD
Hematology & Oncology — Payments: $425,119
Hematology & Oncology $425,119